Literature DB >> 11730938

Microarray analysis of gene expression in multiple sclerosis and EAE identifies 5-lipoxygenase as a component of inflammatory lesions.

L W Whitney1, S K Ludwin, H F McFarland, W E Biddison.   

Abstract

Multiple sclerosis (MS) is a demyelinating disease of the central nervous system characterized by lesions that are areas of blood-brain barrier breakdown, inflammation and myelin damage. To identify genes that contribute to lesion pathology, we have compared gene expression in MS lesions and in brains of mice with experimental allergic encephalomyelitis (EAE) with that in normal white matter. Gene expression was analyzed by cDNA microarrays consisting of 2798 human genes. One of the genes found to be upregulated in both MS lesions and EAE brains was 5-lipoxygenase (5-LO), a key enzyme in the biosynthesis of the proinflammatory leukotrienes. The presence of 5-LO in MS lesions was confirmed by immunohistochemistry and indicated that 5-LO was primarily contained within macrophages. Although these findings are not specific for MS, they identify a potentially important component of pro-inflammatory activity in the demyelinating process in MS and suggest a possible target for anti-inflammatory therapy in MS.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11730938     DOI: 10.1016/s0165-5728(01)00438-6

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  32 in total

1.  Gene-expression profiling of experimental autoimmune encephalomyelitis.

Authors:  Eilhard Mix; Jens Pahnke; Saleh M Ibrahim
Journal:  Neurochem Res       Date:  2002-10       Impact factor: 3.996

Review 2.  Functional genomics and psychiatric illness.

Authors:  Wendy Hasenkamp; Scott E Hemby
Journal:  Prog Brain Res       Date:  2002       Impact factor: 2.453

Review 3.  G protein-coupled receptors as therapeutic targets for multiple sclerosis.

Authors:  Changsheng Du; Xin Xie
Journal:  Cell Res       Date:  2012-06-05       Impact factor: 25.617

Review 4.  Gene expression profiling with DNA microarrays: advancing our understanding of psychiatric disorders.

Authors:  Julie Pongrac; Frank A Middleton; David A Lewis; Pat Levitt; Károly Mirnics
Journal:  Neurochem Res       Date:  2002-10       Impact factor: 3.996

Review 5.  Essential Dietary Bioactive Lipids in Neuroinflammatory Diseases.

Authors:  Maria Valeria Catani; Valeria Gasperi; Tiziana Bisogno; Mauro Maccarrone
Journal:  Antioxid Redox Signal       Date:  2017-07-24       Impact factor: 8.401

Review 6.  Gene expression profiling in neurological disorders: toward a systems-level understanding of the brain.

Authors:  Sergio E Baranzini
Journal:  Neuromolecular Med       Date:  2004       Impact factor: 3.843

Review 7.  Genomics and proteomics: role in the management of multiple sclerosis.

Authors:  Ludwig Kappos; Lutz Achtnichts; Frank Dahlke; Jens Kuhle; Y Naegelin; Rupert Sandbrink; Raija L P Lindberg
Journal:  J Neurol       Date:  2005-09       Impact factor: 4.849

8.  Gene expression profiling in autoimmune noninfectious uveitis disease.

Authors:  Zhuqing Li; Baoying Liu; Arvydas Maminishkis; Sankaranarayana P Mahesh; Steven Yeh; Julie Lew; Wee Kiak Lim; H Nida Sen; Grace Clarke; Ronald Buggage; Sheldon S Miller; Robert B Nussenblatt
Journal:  J Immunol       Date:  2008-10-01       Impact factor: 5.422

9.  Gene expression and genotyping studies implicate the interleukin 7 receptor in the pathogenesis of primary progressive multiple sclerosis.

Authors:  D R Booth; A T Arthur; S M Teutsch; C Bye; J Rubio; P J Armati; J D Pollard; R N S Heard; G J Stewart
Journal:  J Mol Med (Berl)       Date:  2005-08-02       Impact factor: 4.599

10.  Differing roles for members of the phospholipase A2 superfamily in experimental autoimmune encephalomyelitis.

Authors:  Athena Kalyvas; Constantinos Baskakis; Victoria Magrioti; Violetta Constantinou-Kokotou; Daren Stephens; Rubèn López-Vales; Jian-Qiang Lu; V Wee Yong; Edward A Dennis; George Kokotos; Samuel David
Journal:  Brain       Date:  2009-02-13       Impact factor: 13.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.